RedHill Biopharma Licenses RHB-102 to Hyloris for up to $60M

Ticker: RDHL · Form: 6-K · Filed: Feb 25, 2025 · CIK: 1553846

Redhill Biopharma Ltd. 6-K Filing Summary
FieldDetail
CompanyRedhill Biopharma Ltd. (RDHL)
Form Type6-K
Filed DateFeb 25, 2025
Risk Levelmedium
Sentimentbullish

Sentiment: bullish

Topics: licensing-agreement, milestone-payments, drug-commercialization

TL;DR

RedHill inks $60M+ deal with Hyloris for RHB-102 outside North America.

AI Summary

RedHill Biopharma Ltd. announced on February 25, 2025, that it has licensed its drug candidate RHB-102 for worldwide commercialization, excluding North America, to Hyloris. This deal could be worth up to $60 million in potential milestone payments, plus royalties.

Why It Matters

This licensing agreement provides RedHill Biopharma with significant potential non-dilutive funding and expands the global reach of its drug candidate.

Risk Assessment

Risk Level: medium — Milestone payments are contingent on future events and regulatory approvals, and the actual value realized may be less than the headline $60 million.

Key Numbers

  • $60 million — Potential Milestone Payments (Maximum upfront and milestone payments from Hyloris for RHB-102.)

Key Players & Entities

  • RedHill Biopharma Ltd. (company) — Licensor
  • RHB-102 (drug_candidate) — Licensed asset
  • Hyloris (company) — Licensee
  • $60 million (dollar_amount) — Potential milestone payments

FAQ

What is the territory covered by the license agreement?

The license covers worldwide commercialization of RHB-102, excluding North America.

Who is the licensee for RHB-102?

The licensee is Hyloris.

What is the maximum potential value of the milestone payments?

The potential milestone payments are up to $60 million.

Does the agreement include royalties?

Yes, the agreement includes potential milestone payments plus royalties.

What is the drug candidate involved in this agreement?

The drug candidate is RHB-102.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on February 25, 2025 regarding RedHill Biopharma Ltd. (RDHL).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.